Combined therapy for duchenne muscular dystrophy
US10471089B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 10, 2016 |
| Grant date | Nov 12, 2019 |
| Priority date | — |
| Expiry date | Jun 10, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the combined use of antisense oligonucleotides and viral vectors for the treatment of Duchenne muscular dystrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.